The Goodman family acquires GeriatRx and appoints Jonathan Ross Goodman as President and CEO. The company’s initial market capitalization is $1 million.
Mark Beaudet joins Paladin Labs as a Director and Vice President.
The Company’s name is changed from GeriatRx to Paladin Labs Inc.
Paladin’s revenues exceed $10 million for the first time. Market capitalization reaches $85 million.
Paladin’s revenues exceed $50 million for the first time. Market capitalization reaches $150 million.
Paladin’s revenues exceed $100 million for the first time. Market capitalization reaches $345 million.
Paladin Labs enters into an agreement to be acquired by Endo Health Solutions in a cash and stock transaction valuing the company at over $1.6 billion. As part of the transaction consideration, Paladin agrees to create and carve out a new entity to Paladin shareholders, Knight Therapeutics Inc. Knight will own certain rights associated with Impavido, an approved Paladin product indicated for the treatment of leishmaniasis, and be transferred $1 million in cash.
Endo Health Solutions acquisition of Paladin Labs closes for a total transaction value of over $3.0 billion. Knight Therapeutics begins operations as an independent entity and is listed on the TSX-V under the symbol GUD. Jonathan Ross Goodman appointed as founding President and CEO.